Preparation method and application of a high-stability fusion enzyme

By constructing and co-expressing the gene of alkaline enzyme, combined with chemical modification and microcapsule technology, the problem of poor stability of complex enzymes in medical cleaning agents is solved, and the preparation of high-stability fusion enzymes is achieved, which improves the cleaning effect and enzyme activity. .

CN118562843BActive Publication Date: 2024-11-19南京永正生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411065121.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

The composite enzymes in existing medical cleaning agents have poor stability, especially during cleaning in the presence of high temperatures and chemicals, which affect the cleaning effect and the stability of the enzyme preparation.

Method used

通过构建碱性蛋白酶、碱性淀粉酶和碱性脂肪酶的突变基因,利用基因工程技术在大肠杆菌中实现共表达,结合化学修饰和微胶囊技术,提高酶的稳定性和催化性能,形成高稳定性融合酶。

Benefits of technology

It significantly improves the expression amount and stability of fusion enzymes, enhances its resistance to chemical substances in cleaning agents, and improves the washing effect and enzyme activity stability of medical cleaning agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118562843B_ABST
    Figure CN118562843B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of fusion enzymes, and specifically to a preparation method and application of a high-stability fusion enzyme. The preparation method comprises: constructing mutant genes of alkaline protease, alkaline amylase and alkaline lipase respectively; constructing a recombinant vector using a multi-gene co-expression vector pQLinkH; transforming into Escherichia coli to obtain a recombinant co-expression strain; fermenting, separating and purifying to obtain a fusion enzyme; chemical modification; microencapsulation. The present invention greatly improves the expression amount and stability of the fusion enzyme through ultraviolet mutagenesis, genetic engineering technology and in vitro chemical modification, and at the same time uses microencapsulation technology to reduce the destructive effects of other chemical components in the cleaning agent on the fusion enzyme, thereby obtaining a highly stable fusion enzyme, and the prepared fusion enzyme has the activities of alkaline protease, alkaline amylase and alkaline lipase at the same time, and is suitable for preparing medical cleaning agents.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of fusion enzymes, and in particular to a preparation method of a high-stability fusion enzyme and an application thereof. Background Art

[0002] With the continuous development of medical technology, the types and quantity of medical devices are increasing, and the demand for medical cleaning agents is also growing. Traditional medical cleaning agents have problems such as weak decontamination ability, easy foaming, and incomplete cleaning, which are difficult to meet the needs of modern medical cleaning. Enzyme medical cleaning agents have gradually become the mainstream products in the medical cleaning agent market due to their excellent cleaning effect and environmental protection performance.

[0003] In order to improve the cleaning effect of enzyme medical cleaning agents, a cleaning agent usually contains a variety of different enzymes, such as protease for decomposing protein stains (blood, tissue fluid, etc.), lipase for decomposing fat stains, amylase for decomposing starch stains, cellulase for decomposing cellulose stains, etc. However, there are also some problems with compound enzyme medical cleaning agents added with multiple enzymes. The medical enzyme preparations used in them are the most stringent in the field of enzyme preparations. Its preparation standards not only far exceed those of other enzymes, but are also reflected in the strict control of indicators such as colony content, odor, color, and heavy metal content. At the same time, there are also strict requirements on the stability of the enzyme solution.

[0004] As the main active ingredient in complex enzyme medical cleaning agents, the stability of complex enzymes directly determines the cleaning effect of the cleaning agent. The stability of complex enzymes in cleaning agents is not only manifested in thermal stability, but also in stability to surfactants, bleaching agents, chelating agents, etc. in the cleaning agent. For example, the low-foaming surfactants used in medical cleaning agents have undergone significant changes in their physical and chemical properties after low-foam modification. They are no longer friendly to enzyme preparations, but have a strong destructive effect on enzyme preparations, which may seriously affect the stability and efficiency of enzyme preparations during the cleaning process. In addition, different enzymes compounded into complex enzymes will also affect each other, especially proteases will hydrolyze and destroy other enzymes.

[0005] Therefore, developing a complex enzyme with strong stability in medical cleaning agents has become a technical problem that needs to be solved urgently. Summary of the invention

[0006] In order to solve the problem of poor stability of the complex enzyme used in the traditional Chinese medicine cleaning agent in the prior art, the present invention provides a preparation method of a high-stability fusion enzyme and its application.

[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0008] In the first aspect, the present application provides a method for preparing a high-stability fusion enzyme, and the technical solution adopted is as follows:

[0009] A method for preparing a high-stability fusion enzyme comprises the following steps:

[0010] S1: construct the mutant gene of alkaline protease, the mutant gene of alkaline amylase and the mutant gene of alkaline lipase respectively;

[0011] S2: connecting the alkaline protease mutant gene, the alkaline amylase mutant gene and the alkaline lipase mutant gene to the multi-gene co-expression vector pQLinkH to obtain a recombinant vector;

[0012] S3: transform into Escherichia coli DH5α expression strain to obtain recombinant strain;

[0013] S4: inoculating into culture medium, fermenting, separating and purifying to obtain fusion enzyme;

[0014] S5: Chemical modification of the fusion enzyme;

[0015] S6: Microencapsulation to obtain a highly stable fusion enzyme.

[0016] Preferably, in S1, the method for constructing the alkaline protease mutant gene comprises:

[0017] The method comprises the following steps: selecting a Bacillus licheniformis capable of expressing alkaline protease as a starting strain, preparing protoplasts, subjecting the strain to ultraviolet mutagenesis treatment, screening the strain, obtaining a mutant strain with high alkaline protease production, extracting genomic DNA, obtaining an alkaline protease mutant gene by PCR, sequencing the gene, further optimizing and modifying the codons of the gene sequence, obtaining an alkaline protease mutant gene sequence, and artificially synthesizing an alkaline protease mutant gene.

[0018] Preferably, in S1, the method for constructing the alkaline amylase mutant gene comprises:

[0019] Bacillus cereus capable of expressing alkaline amylase is selected as a starting strain, protoplasts are prepared, ultraviolet mutagenesis treatment is performed, strain screening is performed, a mutant strain with high alkaline amylase production is obtained, genomic DNA is extracted, PCR is used to obtain an alkaline amylase mutant gene, gene sequencing is performed, the codons of the gene sequence are further optimized and modified, the alkaline amylase mutant gene sequence is obtained, and the alkaline amylase mutant gene is artificially synthesized.

[0020] Preferably, in S1, the method for constructing the alkaline lipase mutant gene comprises:

[0021] Bacillus subtilis capable of expressing alkaline lipase is selected as a starting strain, protoplasts are prepared, ultraviolet mutagenesis treatment is performed, strain screening is performed, a mutant strain with high alkaline lipase production is obtained, genomic DNA is extracted, PCR is used to obtain an alkaline lipase mutant gene, gene sequencing is performed, the codons of the gene sequence are further optimized and modified, the alkaline lipase mutant gene sequence is obtained, and the alkaline lipase mutant gene is artificially synthesized.

[0022] Preferably, in S5, chemically modifying the fusion enzyme comprises the following steps:

[0023] Using maleic anhydride as a modifier, 100 ug / mL of maleic anhydride was added to the fusion enzyme solution and stirred at 25°C and 200 r / min for 8 hours.

[0024] Preferably, in S6, the microencapsulation comprises the following steps:

[0025] The chemically modified fusion enzyme is freeze-dried to obtain fusion enzyme powder, and the fusion enzyme powder is wrapped with fatty acid and polyanion polysaccharide as a wrapping layer to obtain microencapsulated fusion enzyme.

[0026] Preferably, the nucleotide sequence of the alkaline protease mutant gene is shown as SEQ ID NO.1; the nucleotide sequence of the alkaline amylase mutant gene is shown as SEQ ID NO.2; and the nucleotide sequence of the alkaline lipase mutant gene is shown as SEQ ID NO.3.

[0027] In the second aspect, the present application provides a high-stability fusion enzyme, and the technical solution adopted is as follows:

[0028] A high-stability fusion enzyme is prepared according to the above-mentioned method for preparing a high-stability fusion enzyme.

[0029] Preferably, the high-stability fusion enzyme has the activities of alkaline protease, alkaline amylase and alkaline lipase simultaneously.

[0030] Preferably, the high-stability fusion enzyme is used in a medical cleaning agent, and the medical cleaning agent is used to wash medical equipment, operating tables, doctor's work clothes, patient clothes, etc.

[0031] Based on the above technical solutions, this application has the following beneficial effects:

[0032] 1. The present invention respectively performs ultraviolet mutagenesis on strains producing alkaline protease, alkaline amylase and alkaline lipase and screens high-expression strains of the corresponding enzymes, amplifies mutant genes of the corresponding enzymes in the high-expression strains by PCR, and optimizes the sequences of the mutant genes by using the codon preference of Escherichia coli, and finally obtains mutant genes of the three enzymes, realizes stable and efficient expression of the corresponding enzymes, and fundamentally improves the expression amount and stability of each enzyme in the fusion enzyme.

[0033] 2. The present invention adopts genetic engineering technology to construct a co-expression vector of three genes, and the mutant genes of the three enzymes to be compounded are simultaneously constructed on the same expression vector, and then transformed into the same expression strain for overall expression. Through the coordination, integration, repair and other functions of the bacteria itself, the required fusion enzyme is expressed at one time, and after the integration of the bacteria, the other enzymes and the protease have been integrated. At this time, the protease no longer attacks other coexisting enzyme preparations, thereby enhancing the stability of the fusion enzyme.

[0034] 3. The present invention performs in vitro protein modification on the co-expressed fusion enzyme to further enhance the stability and catalytic performance of the enzyme.

[0035] 4. The present invention uses microcapsule technology to encapsulate the chemically modified fusion enzyme, which can resist the damage to the enzyme by other chemical substances in the cleaning solution.

[0036] In summary, the present invention greatly improves the expression level and stability of the fusion enzyme through ultraviolet mutagenesis, genetic engineering technology and in vitro chemical modification, and simultaneously utilizes microencapsulation technology to reduce the destructive effects of other chemical components in the cleaning agent on the fusion enzyme, thereby forming a fusion enzyme with high stability and suitable for medical cleaning agents. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the specific implementation of the present invention or the technical solution in the prior art, the drawings required for use in the specific implementation or the description of the prior art are briefly introduced below.

[0038] Figure 1 It is a flow chart of constructing a recombinant expression vector using the multi-gene co-expression vector pQLinkH. DETAILED DESCRIPTION

[0039] The present invention has used the conventional techniques and methods used in microbial mutagenesis breeding, genetic engineering and molecular biology field, for example MOLECULAR CLONING: A LABORATORY MANUAL, 3rd Ed. (Sambrook, 2001) and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel, 2003) in the method of recording. These general references provide definition and method known to those skilled in the art. But those skilled in the art can, on the basis of the technical scheme recorded in the present invention, adopt other conventional methods, experimental schemes and reagents in this area, and are not limited to the limitation of specific embodiments of the present invention.

[0040] Example 1: A method for preparing a high-stability fusion enzyme, comprising the following steps:

[0041] S1: Construction of enzyme mutant gene

[0042] 1. Construction of alkaline protease mutant gene

[0043] (1) Selecting Bacillus licheniformis that can express alkaline protease as the starting strain and preparing Bacillus licheniformis protoplasts. The specific preparation process is as follows:

[0044] Pick a fresh single colony, inoculate it into a 250 mL Erlenmeyer flask containing 25 mL of growth medium, and culture it at 37 °C for 12 h;

[0045] Take the overnight culture solution and transfer 500 μL of inoculum into 25 mL of growth medium. Shake and culture for about 4 to 4.5 hours until the early logarithmic phase.

[0046] Transfer the bacterial solution into a 50mL centrifuge tube, place in an ice bath for 10 minutes, centrifuge at 4°C and 3500r / min to remove the supernatant, resuspend the bacteria with 5mL of SMMP solution, add 70μL of 100mg / mL lysozyme, and place in a shaker at 37°C and 100r / min for about 30 minutes to lyse until 70%-90% of the bacteria become protoplasts;

[0047] Then 15 mL of SMMP solution was added, the mixture was gently mixed, and the mixture was centrifuged at 4°C and 1900 r / min. The supernatant enzyme solution was removed and the mixture was resuspended in 500 μL SMMP to obtain protoplast fluid.

[0048] (2) UV mutagenesis treatment: The protoplast fluid was treated with UV, UV-NaN3, and UV-EMS for 1, 2, 3, and 4 min respectively under a 15 W UV lamp (wavelength 2537 Å) at a distance of 29 cm and electromagnetic stirring.

[0049] (3) Strain screening: Gently add 5 mL of SMMP solution, centrifuge at 4°C and 2500 r / min, gently pour out the supernatant, do not pour out the precipitate, keep a small amount of supernatant, add 200 µL of SMMP solution to the precipitate at the bottom of the centrifuge tube, gently mix, and culture at 30°C and 100 r / min for two and a half hours to obtain a mutant strain with protoplast regeneration; spread it on DM3 medium containing erythromycin resistance, and resuscitate at 37°C for 1 day. Pick the regenerated colonies, inoculate the spore culture medium, and treat the spores at 80°C for 20 minutes twice to screen out high-yield stable mutant strains with good thermal stability and high enzyme activity.

[0050] (4) Extracting the genomic DNA of the high-yield stable strain obtained by screening, using the genomic DNA as a template and primer sequence for PCR amplification to obtain the alkaline protease mutant gene, sequencing the gene, and further optimizing and modifying the codons of the gene sequence according to the codon preference of Escherichia coli to finally obtain the alkaline protease mutant gene sequence, as shown in SEQ ID NO.1. The specific sequence is as follows:

[0051] ATGATGAGGAAAAAGAGTTTTTGGCTTAGGATTCTGACGGCCTTAATGCTCGTGCTCACGATGG

[0052] CGTTCAGCGTTCCGCGTCAGCTGCTCAGCCGGCGAAAAAATGTTGAAAAGGATTATATTGTCGGA

[0053] TTTAAGTCGGGAGTGAAAACCGCATCCGTCTAAATTGACATCATCAAAGAGAGCGGCGGAAAAGT

[0054] GGACAAGCAGTTTAGAATCATCAACGCGGCAAAAGCGAAGCTAGACAAAGAAGCGCTTGAGGAAGT

[0055] CAAAAATGATCCGGATGTCGCTTATGTGGAAGAGGATCACGTAGCTCATGCTTTTGGCGCAAACCCT

[0056] TCCTTACGGCATTCCTCTCATTAAAGCGGACAAAGTGCAGGCTCAAGGCTACAAGGGAGCGAACGT

[0057] AAAAGTCGCCGTCCTGGATACAGGAATCCAAGCTTCTCATCCGGACTTGAACGTAGTCGGCGGAGC

[0058] AAGCTTCGTAGCTGGCGAAGCTTATAACACCGACGGCAACGGACACGGCACGCATGTTGCCGGTAC

[0059] AGTAGCTGCGCTTGACAATACAACGGGTGTACTAGGCGAACCGCCGAACGTATCCTTGTACGCGGT

[0060] TAAAGTGCTGAATTCAAGCGGAAGCGGATCTTACAGCGGCATTGTAAGCGGAATCGAGTGGGCGAC

[0061] GACAAACGGCATGGATGTTATCAACATGAGCCTTGGAGGACCATCAGGCTCAACAGCGTTGAAACA

[0062] GGCGGTTGACAATGCATATGCAAGAGGGGTTGTCGTTGTGGCGGCTGCTGGGAACAGCGGATCTTC

[0063] AGGAATCACGAATACCATCGGCTATCCTGCGAAATACTACTCTGTAATCGCAGTTGGCGCGGTAGA

[0064] CTCTAACAGCAACAGAGCTTCATTTTCCAGCGTCGGAGCAGAGCTTGAAGTCATGGCTCCTGGCGC

[0065] AGGCGTGTACAGCACTTACCCAACCAGCACTTATGCAACATTGAACGGAACGTCAATGGCTTCACC

[0066] TCATGTAACGGGAGCAGCAGCTTTGATCTTGTCAAAACATCCGAACCTTTCAGCTTCACAAGTCCG

[0067] CAACCGTCTCTCCAGTACGGCGACTTATTCGGGAAGCTCCTTCTACTATGGAAAAGCTCTCATCAA

[0068] TGTCGAAGCTTCCGCTCAATAA

[0069] (5) Based on the above sequence, Wuhan Jinkairui Biotechnology Co., Ltd. artificially synthesized the alkaline protease mutant gene.

[0070] 2. Construction of alkaline amylase mutant gene

[0071] (1) Select Bacillus cereus that can express alkaline amylase as the starting strain and prepare it into protoplasts. The specific preparation process refers to the preparation process of Bacillus licheniformis protoplasts.

[0072] (2) UV mutagenesis treatment: refer to the UV mutagenesis steps for Bacillus licheniformis protoplasts.

[0073] (3) Strain screening: Refer to the strain screening steps of Bacillus licheniformis to screen out high-yield stable mutant strains with good thermal stability and high enzyme activity.

[0074] (4) Referring to the construction steps of the alkaline protease mutant gene in Bacillus licheniformis, the alkaline amylase mutant gene sequence was obtained, as shown in SEQ ID NO.2. The specific sequence is as follows:

[0075] ATGTTGCTTCTAAACTGAGCGAAGCGCGGCTGAAGCTGTTTGTGCTGCTGGCTCTGTTTGGGCTCAGTGT

[0076] GGCCCAACACAACCCTCACCTCAGGCAGGGGAGGACATCCATCGTTCACCTGTTTGAGTGGCGCTGGGCC

[0077] GACATTGCTGAAGAGTGCGAGCGCTTCTTGGGTCCATCCGGCTTCGGTGGAGTTCAGGTATGAATGGTTT

[0078] CTATGGGGATGACATCACATCCGTTTCATCAAGGACTGTCAAATAATTCAAACTTTTTATCTGATTAAT

[0079] CATGATTAATTGTGATAAATCAACACAGAAAATTCTGTATACTACTGTGCAAGGAAGACAGATAATGGTA

[0080] GTAAATTATAATTTTTTAACACCAAATTTTAAACTTGTGACTAACAACATAAATAAATTATTAATATGGA

[0081] AATATGTCAAGAAACAATTGCAAAAGTAAAAATGATCTATATAATCTATATCCCCTGCAATACTTGTTTA

[0082] TGCAGCAGTGCCATAACAACTCTGTTTATAAGAAACAAACTTGTATTTCAACTGGTCCCAATCGTCATCT

[0083] GTTTGTCCCTCAGATCTCCCCTCCAAATGAGCACATCGTGCTCGGCTCCCCCTGGAGGCCCTGGTGGCAG

[0084] AGATACCAGCCCATCAGCTACAACCTGTGCTCCAGATCTGGTAGTGAGTCTGAACTGAGAGACATGATCA

[0085] CCAGATGCAACAACGTCGGGGTAAAGAAGCCATTGGGCCACTCTTCCTGTTACCACCTCTACACCAAAGT

[0086] GATTTTAATTAAAATCTGCCAAAAACCTTTCCTTCAGGTCAACATCTACGTGGACGCCGTCATCAACCAC

[0087] ATGTGTGGAGCTGGTGGTGGAGAAGGAACACACTCCTCATGTGGCAGCTGGTTCAACGCCGGCACCAAAG

[0088] ACTTCCCCAGCGTTCCTTCTTCCAACTTGGACTTTAAGAACTACAAATGCAGGACATCCAGTGGAAATAT

[0089] TGAGAACTACAGCGATAAACATCAGGTAATGTGTCACTATTTACACCGAGTACATTTGAACACATTTACT

[0090] GCAGTAATAAAGACTATAAAACACACGAGTATTCATGGTTCCAGGTGCGTGACTGTCGTCTGGTCAGTCT

[0091] GCTGGATCTGGCTCTGGAGAAGGACTTTGTTCGGGACAAGGTGGCCGACTTCATGAACAAACTGATCGAC

[0092] ATGGGCGTGGCCGGATTCAGGGTGGATGCCGTCAAGCACATGTGGCCTGGAGACCTCGACGCTGTCTCTC

[0093] GTCGTCTGCATAACCTGAACTCTAAGTGGTTCCCCGATGACGCCAAACCCTTCATCTTCCAAGAGGTGCT

[0094] TTAAAAAAAAAAGTGATTTTAAGGAATAAAATAAATAGTTATGAAGGATAAAAGATAAGTTTAACATCAG

[0095] TGAGGTCCTGGCACTCATCATCAGGTAATGTCAAATAGTCATGGCCCCTAAAGAAATTACAAGCAAATTA

[0096] AAGCAGAGCAGAGCAGAGAAAGAGACAGACTTATGATAGAAAACATCAGAAACATCACAGCGCTTTGTGA

[0097] AAGTTATGAGTTTTTAAAATCTGTAATTCCCACAGAGATGTCAGTCTGTGGTTAAATCCTGTCTTTGTTT

[0098] ATTGGAGATTTTTTTTGTGGCTTTTTCTGTAGCACACTGCTCTGAAAAGACGTGGTTGACATCAATTTTC

[0099] TGGGGGTCTTTTTTCCATTAGGTTATTGATCTGGGAGGTGAGGCTATTTCAGCTCCAGAGTATTTCCATC

[0100] TGGGAAGGGTGACGGAGTTCAAATACGGTGCGAAACTGGGAACTGTGTTCAGAAAATGGAACAACGAGAA

[0101] GCTGTGTTACACCAGGTGTGAGCTGTTCTACGGGAAACGAAAAGAAGCTTTTCTATCGCCTGTGCTCATT

[0102] TGTTTTTTTCTTCCTCTTGTCTACAGAAACTGGGGAGAAGGCTGGGGCTTCATGCCCAATGGGAACGCCC

[0103] TGGTCTTCATTGACAACCATGACAACCAGAGAGGCCATCCAGCAGGCGGTGCGGCCATCCTGACTTTCTG

[0104] GGACCCAAGGCTTTACAAAATGAGCGTGGGCTTCATGCTGGCCCACCCATACGGAGTAACCAGAGTGATG

[0105] TCCAGCTTCCACTGGGACCGCCACTTTGTGAATGGAAAGGTAGACTTACGTAACACCAGTACAACGTTAC

[0106] ATGACCTGTGGCTCTATCAGATGCAATAATCAATTTTGATGTAGGACCAGAACGACTGGATGGGCCCCCC

[0107] CAGCCACGGTAACGGATCCACCAAGCCCGTCCCCATCAAACCAGACCAGACCTGTGGAGACGGGTGGGTG

[0108] TGTGAGCACAGATGGCGACAAATCAAGTGAGTTCTCATTATCTGGGTCTGTTACTCTGCCAGTAATGTAA

[0109] ATGTCATCTAAAAAAGGTTCTGATTGTTGTTATCTCCACTTTAGGAACATGGTCATCTTCCGTAATGTGG

[0110] TCAACGGACAACCTTTCACCAACTGGTGGCACAACAACAGTAATCAGGTTGCCTTTGGACGTGGTAACCG

[0111] CGGGTTTATCGTCTTTAACAACGATGACTGGTGAGAAACAAACCCAAACTAATGAGATGAAATGATTTTG

[0112] TTTAAAGTTACCTGGAAATTTCGGTCATCTGATCAATAACAATATTGGTTTGTTCCTGTTTTCATCTTGT

[0113] TGTTACTTGTCACCACCCCCCGACACACAGGGATCTGAACATGACCCTCAGCACTGGTTTGCCCGGTGGA

[0114] GTCTACTGTGATGTCATTTCTGGACAGAAGCAAGGAAATGCCTGTACTGGGAAGCAGATCCACGTGGGCA

[0115] GTGACGGCCGTGCTCACTTCTTCATCAGCAAGATAGATGAGGATCCATTTCTTGCTATTCATGTCGATGC

[0116] AAAGCTCTGAATACATGAATAAATAAAAATAAAGACAATTATAATTTTCAATGTAAAAATAATAAAGGAG

[0117] CAAATTGGCG

[0118] (5) Based on the above sequence, Wuhan Jinkairui Biotechnology Co., Ltd. artificially synthesized the alkaline amylase mutant gene.

[0119] 3. Construction of alkaline lipase mutant gene

[0120] (1) Select Bacillus subtilis that can express alkaline lipase as the starting strain and prepare it into protoplasts. The specific preparation process refers to the preparation process of Bacillus licheniformis protoplasts.

[0121] (2) UV mutagenesis treatment: refer to the UV mutagenesis steps for Bacillus licheniformis protoplasts.

[0122] (3) Strain screening: Refer to the strain screening steps of Bacillus licheniformis to screen out high-yield stable mutant strains with good thermal stability and high enzyme activity.

[0123] (4) Referring to the construction steps of the alkaline protease mutant gene in Bacillus licheniformis, the alkaline lipase mutant gene sequence was obtained, as shown in SEQ ID NO.3. The specific sequence is as follows:

[0124] ATGGATTCATCCACTTTCGCAAACTCGCAGCGAGCGGCCGAGCTCTCCTCTGAGGCCAATACAGGCTGCG

[0125] TGGCTTCTGCTTTCGATGTCACCATCACCAAACAGATCTATAATTTGGTAACCGATTCGCAGATGCCTTG

[0126] CCCTATAGTTCATCGAGAATCATAGTCTGGCTGGACCATCGCCCACACGTGCCATGACCCTAGGGTTATA

[0127] TCGGCTATTCGATGGCGAAGAAGTCCATCGGCAGTCGTCATGAGAGGATCGACCACGGCCACGGATATCCT

[0128] CAACGACGTCGACACCATCCAGGTCACCACGACCCTGGCTGGCGTTAGCTTGCCCTCCAGCGTCACCATC

[0129] ATGAACGGCGTGTACAGATCCTGGGCCGCCGTCACGACGAAGTCATCGCCGATGTCCAGAGCCTGATCAT

[0130] CCAGTATCCCGGCTATGCACTCGAGCCCACAGGACACTCGCTTGGTGGAGCCCTGACGCACGTAGATGTC

[0131] TTGTATCGCTTTGGCGCAGAAGTTCCCAACTACGTCGCTCAGAAGCCATGCGCTCGCGGGCATTTCCAATT

[0132] GGCAACCAGGCATTTGCCGACTTTGGCACTACGCAGAACGGGAACGCGGATTCGGGGAAACAATGCGAAT

[0133] GATGGTGTTCCTGTAAGTGCTGCTGGGCAGTGAGGCGCTGATTAGAACTGTACGTTAGTGCTAACGCTAT

[0134] GAGCTATCAGAATATGTATGTCACGACGCCGTATAACTTTGTCATTATGGAATTGTAAATCTCTCCGTG

[0135] CTTGATTTCGGGGTCTCGAGTCCATGAGCCAAGCTATCGATGATTTCTGTTTCTTGCTCAGTCGGTGTATC

[0136] TGTAGGATTACTACAGCTACGGTAGTACTTTGGCCACTACAAATGCTCTGGCGAGAGGGATCCGCAGGGT

[0137] GTGGAGTCTAGATTCATCTCAAGCGATGTTGCGCTGTACAGAGCGCTTTGTCGCTTCACGGCGGAGGTAT

[0138] TCGCTGGCTGGAAGAATGAAGATAGGGTACATGGTTGTGAGGAGCAAGAGGGCGTGTTTCGCTTTGATCT

[0139] GATCTGA

[0140] (5) Based on the above sequence, Wuhan Jinkairui Biotechnology Co., Ltd. artificially synthesized the alkaline amylase mutant gene.

[0141] In the step of constructing mutant genes, the PCR primer pairs used to amplify the alkaline protease mutant gene, the alkaline amylase mutant gene and the alkaline lipase mutant gene are respectively as follows:

[0142] Alkaline protease primer sequence:

[0143] Upstream primer: 5'-ATGAGTTGCTAGCATTACTTCTG-3' (SEQ ID NO.4);

[0144] Downstream primer: 5'-TTGCTTCCCACATTGGTTCG-3' (SEQ ID NO. 5);

[0145] Alkaline amylase primer sequences:

[0146] Upstream primer: 5'-ATCGTAGCTCCTAAACAGAGCGAACCGTGGC-3' (SEQ ID NO.6);

[0147] Downstream primer: 5'-ATCGCTGCCTGATGCTCTTCGTTTAACGC-3' (SEQ ID NO. 7);

[0148] Alkaline lipase primer sequences

[0149] Upstream primer: 5'-CGCCGGATCCGACCAAGTTGTTCAACTAC-3' (SEQ ID NO.8);

[0150] Downstream primer: 5'-CCGGACTTAATCAGCACAGCTTAGCCACAA-3' (SEQ ID NO.9).

[0151] S2: Construction of recombinant expression vector

[0152] According to the instruction manual of the pQLinkH vector of Shanghai Lianmai Biotechnology Co., Ltd., the artificially synthesized alkaline protease mutant gene, alkaline amylase mutant gene and alkaline lipase mutant gene were ligated to the multi-gene co-expression vector pQLinkH to obtain a recombinant expression vector. The construction scheme is as follows: Figure 1 As shown in the figure, gene No. 1 is an alkaline protease mutant gene, gene No. 2 is an alkaline amylase mutant gene, and gene No. 3 is an alkaline lipase mutant gene.

[0153] S3: Construction of recombinant expression strains

[0154] 1. Strain recovery and cultivation

[0155] Take out the E. coli DH5α strain from the -80℃ freezer, use a sterilized pipette tip to draw a small amount of bacterial solution and add it to the LB liquid medium, and culture it in a shaking incubator at 37℃ overnight. The next day, pick a moist and smooth single colony of E. coli from the LB solid medium, inoculate it into the LB liquid medium without antibiotics, and continue to culture it at 37℃ with shaking until the late logarithmic growth stage.

[0156] 2. Preparation of competent cells

[0157] Dilute the bacterial solution in the logarithmic growth phase and inoculate it into a new LB liquid medium. Cultivate at 37°C with shaking until the OD600 reaches 0.5. Transfer the bacterial solution to a pre-cooled centrifuge tube on ice under sterile conditions. Place it on ice for a period of time and then centrifuge to collect the bacteria. Gently suspend the cells with a pre-cooled CaCl2 solution, place it on ice again and centrifuge it. Finally, add a CaCl2 solution containing glycerol to suspend the cells to prepare a competent cell suspension.

[0158] 3. Conversion

[0159] Add the recombinant expression vector prepared in S2 to the competent cell suspension, mix gently and place on ice for a while. Place in a 42°C water bath for 90 seconds for heat shock treatment, then quickly cool in an ice bath for 2 minutes. Add LB medium and resume culture for 1 hour to allow the bacteria to recover and express the resistance gene.

[0160] 4. Screening and identification

[0161] The recovered bacterial solution was spread on the LB solid medium containing ampicillin, and the coated plate was placed in a 37°C constant temperature incubator and inverted for overnight culture. Several single colonies were picked from the plate and inoculated into LB liquid medium containing ampicillin for expansion culture. The cultured bacterial solution was identified by PCR, enzyme digestion, and sequencing to obtain recombinant Escherichia coli DH5α containing the recombinant expression vector.

[0162] S4: Fermentation to prepare fusion enzyme

[0163] 1. Seed culture

[0164] The recombinant E. coli DH5α positive clone described in S3 was inoculated into LB liquid culture medium containing ampicillin and cultured to the logarithmic growth phase.

[0165] 2. Fermentation culture

[0166] The seed culture solution was inoculated into a fermenter and cultured to the mid-logarithmic growth period. 1.0 mmol / L IPTG solution was added as an inducer and the culture was continued to induce the expression of the fusion enzyme.

[0167] 3. Separation and purification

[0168] After the fermentation is completed, the fermentation liquid is centrifuged to collect the bacterial cells. Ultrasonic waves are used to break the cell walls to release the recombinant protein in the cells. The recombinant protein is separated and purified using conventional protein purification technology to obtain the fusion enzyme.

[0169] S5: Chemical modification

[0170] Using maleic anhydride as a modifier, a maleic anhydride solution with a concentration of 100 ug / mL was added to the fusion enzyme solution, and stirred at 25°C and 200 r / min for 8 hours to obtain a maleic anhydride-modified fusion enzyme;

[0171] S6: Microencapsulation

[0172] The enzyme preparation was microencapsulated using the "Method for Preparing Encapsulated Bioenzyme Preparations" with patent number CN114807113.B of our company to obtain a highly stable fusion enzyme.

[0173] Example 2: This example provides a medical cleaning agent, comprising: 15% fusion enzyme, 3% non-ionic surfactant fatty alcohol polyoxyethylene ether sulfate, 10% enzyme stabilizer sodium alginate, 0.8% antiviral and antibacterial agent allicin, 2% rust inhibitor calcium propionate, 0.5% pH adjuster citric acid, 1% preservative sodium benzoate, and the balance is deionized water. The fusion enzyme is the fusion enzyme prepared in Example 1.

[0174] Comparative Example 1: A medical cleaning agent, comprising: 15% of a complex enzyme, 3% of a non-ionic surfactant fatty alcohol polyoxyethylene ether sulfate, 10% of an enzyme stabilizer sodium alginate, 0.8% of an antiviral and antibacterial agent allicin, 2% of a rust inhibitor calcium propionate, 0.5% of a pH adjuster citric acid, 1% of a preservative sodium benzoate, and the balance being deionized water, wherein the complex enzyme comprises 5% of alkaline protease, 5% of alkaline amylase, and 5% of alkaline lipase.

[0175] Experimental Example 1: This experimental example conducts an enzyme solution stability test on the medical cleaning agents provided in Example 2 and the comparative example. The specific experimental steps are as follows:

[0176] The medical cleaning agent was stored at room temperature (25°C) for three months or treated in a 40°C water bath for three months, and then the enzymatic activities of alkaline protease, alkaline amylase and alkaline lipase in the medical cleaning agent were detected using conventional enzyme activity detection methods.

[0177] The experimental results are shown in the following table:

[0178] Table 1 Comparison of enzyme solution stability

[0179]

[0180] Analysis of experimental results: According to Table 1, after being stored at room temperature (25°C) for three months or treated in a water bath at 40°C for three months, the activities of alkaline protease, alkaline amylase and alkaline lipase of the fusion enzyme in the medical cleaning agent of Example 2 did not change significantly, while the activities of the three enzymes in the medical cleaning agent of the comparative example all decreased to varying degrees, especially after being treated in a water bath at 40°C for three months, the enzyme activity decreased by about 20%. Therefore, the enzyme activity stability of the medical cleaning agent of Example 2 is higher than that of the medical cleaning agent of the comparative example, indicating that the fusion enzyme prepared by the present invention has high stability.

[0181] Experimental Example 2: This experimental example conducts a washing effect experiment on the medical cleaning agents provided in Example 2 and the comparative example. The specific experimental steps are as follows:

[0182] Dilute the medical cleaning agent with pure water at a ratio of 1:100, heat it to 40 degrees Celsius, put the medical surgical instruments in, soak for 10 minutes, and rinse with running water. Use conventional detection methods to detect the residual protein, starch and fat on the medical surgical instruments after washing.

[0183] The experimental results are shown in the following table:

[0184] Table 2 Comparison of washing effects of medical cleaning agents

[0185]

[0186] Analysis of experimental results: According to Table 2, after soaking in the medical cleaning agent of Example 2 and the medical cleaning agent of the comparative example for 10 minutes, no protein, starch and fat remain on the surface of the medical surgical instrument in Example 2, while there are still residual proteins, starch and fat on the surface of the medical surgical instrument in the comparative example. Therefore, the washing effect of the medical cleaning agent of Example 2 is better than that of the medical cleaning agent of the comparative example, indicating that the fusion enzyme prepared by the present invention has higher activity.

[0187] Therefore, based on the above technical solutions, the fusion enzyme prepared by the present invention has high stability and has the activities of alkaline protease, alkaline amylase and alkaline lipase; the expression level and stability of the fusion enzyme are greatly improved through ultraviolet mutagenesis, genetic engineering technology and in vitro chemical modification, and the microencapsulation technology is used to reduce the destructive effect of other chemical components in the cleaning agent on the fusion enzyme, thereby obtaining a highly stable fusion enzyme, and the prepared fusion enzyme is suitable for preparing medical cleaning agents.

[0188] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A method for preparing a high-stability fusion enzyme, characterized in that: The following steps are involved: S1: constructing an alkaline protease mutant gene, an alkaline amylase mutant gene and an alkaline lipase mutant gene respectively; the nucleotide sequence of the alkaline protease mutant gene is shown in SEQ ID NO.1; the nucleotide sequence of the alkaline amylase mutant gene is shown in SEQ ID NO.2; The nucleotide sequence of the alkaline lipase mutant gene is shown in SEQ ID NO.3; S2: connecting the alkaline protease mutant gene, the alkaline amylase mutant gene and the alkaline lipase mutant gene to the multi-gene co-expression vector pQLinkH to obtain a recombinant vector; S3: transform into Escherichia coli DH5α expression strain to obtain recombinant strain; S4: inoculating into culture medium, fermenting, separating and purifying to obtain fusion enzyme; S5: Chemical modification of the fusion enzyme; S6: Microencapsulation to obtain a highly stable fusion enzyme.

2. The method for preparing a high-stability fusion enzyme according to claim 1, characterized in that: In S5, chemical modification of the fusion enzyme includes the following steps: using maleic anhydride as a modifying agent, adding 100 ug / mL of maleic anhydride to the fusion enzyme solution, and stirring at 25° C. and 200 r / min for 8 hours.

3. The method for preparing a high-stability fusion enzyme according to claim 1, characterized in that: In S6, the microencapsulation comprises the following steps: freeze-drying the chemically modified fusion enzyme to obtain fusion enzyme powder, and using fatty acid and polyanionic polysaccharide as a coating layer to encapsulate the fusion enzyme powder to obtain microencapsulated fusion enzyme.

4. A high stability fusion enzyme, characterized in that: The high-stability fusion enzyme is prepared according to the method for preparing a high-stability fusion enzyme according to any one of claims 1-3.

5. A high-stability fusion enzyme according to claim 4, characterized in that: The high-stability fusion enzyme has the activities of alkaline protease, alkaline amylase and alkaline lipase simultaneously.

6. Use of a high-stability fusion enzyme as claimed in claim 4 or 5 in a medical cleaning agent.